Oncology

LETTER TO THE EDITOR.

Stage IV NSCLC patients with metastatic SCC showed significantly improved survival when necitumumab, an EGFR-targeted antibody, was combined with gemcitabine and cisplatin (11.5 months), compared to chemotherapy alone (9.9 months).

Every person covered by Medicare would shell out an additional $3 a month if the government agreed to pay to screen certain current and former smokers for lung cancer, a new study estimates.

NCCN Guidelines Updates

NCCN Guidelines Updates

NCCN Guidelines Updates

NCCN Guidelines Updates

NCCN guidelines Updates

NCCN Guidelines Updates

NCCN Guidelines Updates

NCCN Guidelines Updates

NCCN Guidelines Updates

University of Chicago's Comprehensive Cancer Center received $3.9 million from the NCI as the Lead Academic Participating Site for the new NCTN initiative.

MedImmune and Incyte are planning the initiation of a collaborative Phase I/II study to test the efficacy of MedImmune's PD-L1 inhibitor MEDI4736 with Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360.

Britain's healthcare cost-effectiveness agency, NICE, has recommended against using Zytiga in chemotherapy-naive prostate cancer patients.

A study published in the journal Breast Cancer Research and Treatment identified increased incidence of triple negative breast cancer in black women compared to white women, while those with Asian heritage were found more susceptible to HER2-positive breast cancer.

Sequenta's ClonoSIGHT that uses next generation sequencing to detect minimal residual disease, provides prognosis on relapse and survival of post-transplant ALL patients.